Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S. obesity market dynamics remain uncertain. Novo’s catalyst path is “skewed to the downside,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Genmab upgraded to Neutral from Underperform at Exane BNP Paribas
- Hims & Hers jumps ahead of controversial Super Bowl ad airing
- Novo Nordisk Executives Report Share Transactions in Compliance with Market Regulations
- Viking Therapeutics price target lowered to $70 from $120 at Maxim
- Hims & Hers Stock (HIMS) Falters on Backlash Over Super Bowl Ad